Titre : Complexe répresseur Polycomb-1

Complexe répresseur Polycomb-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Complexe répresseur Polycomb-1 : Questions médicales les plus fréquentes", "headline": "Complexe répresseur Polycomb-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Complexe répresseur Polycomb-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Complexe répresseur Polycomb-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines du groupe Polycomb", "url": "https://questionsmedicales.fr/mesh/D063146", "about": { "@type": "MedicalCondition", "name": "Protéines du groupe Polycomb", "code": { "@type": "MedicalCode", "code": "D063146", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.780.890" } } }, "about": { "@type": "MedicalCondition", "name": "Complexe répresseur Polycomb-1", "alternateName": "Polycomb Repressive Complex 1", "code": { "@type": "MedicalCode", "code": "D063150", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Haruhiko Koseki", "url": "https://questionsmedicales.fr/author/Haruhiko%20Koseki", "affiliation": { "@type": "Organization", "name": "Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences (RIKEN-IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan; AMED-CREST, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan." } }, { "@type": "Person", "name": "Atsushi Iwama", "url": "https://questionsmedicales.fr/author/Atsushi%20Iwama", "affiliation": { "@type": "Organization", "name": "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan." } }, { "@type": "Person", "name": "Elena Ezhkova", "url": "https://questionsmedicales.fr/author/Elena%20Ezhkova", "affiliation": { "@type": "Organization", "name": "Black Family Stem Cell Institute, The Tisch Cancer Institute, Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: elena.ezhkova@mssm.edu." } }, { "@type": "Person", "name": "Claudia Köhler", "url": "https://questionsmedicales.fr/author/Claudia%20K%C3%B6hler", "affiliation": { "@type": "Organization", "name": "Department of Plant Biology, Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, 75007, Uppsala, Sweden. koehler@mpimp-golm.mpg.de." } }, { "@type": "Person", "name": "Lars Hennig", "url": "https://questionsmedicales.fr/author/Lars%20Hennig", "affiliation": { "@type": "Organization", "name": "Department of Plant Biology, Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, 75007, Uppsala, Sweden." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.", "datePublished": "2022-11-03", "url": "https://questionsmedicales.fr/article/36326841", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00392-022-02120-0" } }, { "@type": "ScholarlyArticle", "name": "Effectiveness of different treatments for odontogenic keratocyst: a network meta-analysis.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36150944", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijom.2022.09.004" } }, { "@type": "ScholarlyArticle", "name": "Herbal Medicines for Rhinosinusitis: A Systematic Review and Network Meta-analysis.", "datePublished": "2023-01-07", "url": "https://questionsmedicales.fr/article/36609950", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11882-022-01060-z" } }, { "@type": "ScholarlyArticle", "name": "Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35840702", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-16146-x" } }, { "@type": "ScholarlyArticle", "name": "Theory and practice of Bayesian and frequentist frameworks for network meta-analysis.", "datePublished": "2022-06-27", "url": "https://questionsmedicales.fr/article/35760451", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjebm-2022-111928" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Facteurs de transcription", "item": "https://questionsmedicales.fr/mesh/D014157" }, { "@type": "ListItem", "position": 5, "name": "Protéines de répression", "item": "https://questionsmedicales.fr/mesh/D012097" }, { "@type": "ListItem", "position": 6, "name": "Protéines du groupe Polycomb", "item": "https://questionsmedicales.fr/mesh/D063146" }, { "@type": "ListItem", "position": 7, "name": "Complexe répresseur Polycomb-1", "item": "https://questionsmedicales.fr/mesh/D063150" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Complexe répresseur Polycomb-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Complexe répresseur Polycomb-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Complexe répresseur Polycomb-1", "description": "Comment diagnostiquer une dysfonction du PRC1 ?\nQuels tests sont utilisés pour évaluer le PRC1 ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels marqueurs sont associés au PRC1 ?\nLe diagnostic est-il basé sur des symptômes cliniques ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Network+Meta-Analysis&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Complexe répresseur Polycomb-1", "description": "Quels symptômes indiquent une anomalie du PRC1 ?\nLe PRC1 est-il lié à des cancers spécifiques ?\nLes troubles neurologiques sont-ils liés au PRC1 ?\nLe PRC1 affecte-t-il le métabolisme ?\nY a-t-il des symptômes généraux associés au PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Network+Meta-Analysis&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Complexe répresseur Polycomb-1", "description": "Peut-on prévenir les anomalies liées au PRC1 ?\nY a-t-il des tests de dépistage pour le PRC1 ?\nLes antécédents familiaux influencent-ils le risque ?\nDes conseils génétiques sont-ils disponibles ?\nL'alimentation joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Network+Meta-Analysis&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Complexe répresseur Polycomb-1", "description": "Quels traitements ciblent le PRC1 ?\nLa chimiothérapie est-elle efficace contre les anomalies du PRC1 ?\nDes traitements expérimentaux existent-ils pour le PRC1 ?\nLe PRC1 peut-il être ciblé par des médicaments spécifiques ?\nLes thérapies combinées sont-elles efficaces pour le PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Network+Meta-Analysis&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Complexe répresseur Polycomb-1", "description": "Quelles complications peuvent survenir avec le PRC1 ?\nLe PRC1 est-il lié à des maladies auto-immunes ?\nLes complications sont-elles réversibles ?\nLe PRC1 affecte-t-il la qualité de vie ?\nY a-t-il des complications neurologiques associées ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Network+Meta-Analysis&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Complexe répresseur Polycomb-1", "description": "Quels sont les facteurs de risque pour le PRC1 ?\nL'âge est-il un facteur de risque pour le PRC1 ?\nLes facteurs environnementaux influencent-ils le PRC1 ?\nLe sexe joue-t-il un rôle dans le risque de PRC1 ?\nLe mode de vie influence-t-il le risque de PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Network+Meta-Analysis&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction du PRC1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des analyses génétiques et des études d'expression génique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le PRC1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de séquençage et des analyses de chromatine sont couramment utilisés." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une biopsie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être nécessaire pour analyser les tissus affectés par le PRC1." } }, { "@type": "Question", "name": "Quels marqueurs sont associés au PRC1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs épigénétiques comme les modifications des histones sont souvent analysés." } }, { "@type": "Question", "name": "Le diagnostic est-il basé sur des symptômes cliniques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes cliniques peuvent orienter le diagnostic, mais des tests spécifiques sont nécessaires." } }, { "@type": "Question", "name": "Quels symptômes indiquent une anomalie du PRC1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies de développement et des troubles de la différenciation cellulaire peuvent survenir." } }, { "@type": "Question", "name": "Le PRC1 est-il lié à des cancers spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations dans le PRC1 sont associées à divers types de cancers, notamment le cancer du sein." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés au PRC1 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre le PRC1 et des troubles neurologiques, mais les recherches sont en cours." } }, { "@type": "Question", "name": "Le PRC1 affecte-t-il le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches indiquent que le PRC1 peut influencer le métabolisme cellulaire et énergétique." } }, { "@type": "Question", "name": "Y a-t-il des symptômes généraux associés au PRC1 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue et des anomalies de croissance peuvent être observés." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies liées au PRC1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage pour le PRC1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de tests de dépistage standardisés pour les anomalies du PRC1." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque d'anomalies du PRC1." } }, { "@type": "Question", "name": "Des conseils génétiques sont-ils disponibles ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques peuvent aider à évaluer le risque et à discuter des options de prévention." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut contribuer à la santé cellulaire, mais ne prévient pas spécifiquement les anomalies du PRC1." } }, { "@type": "Question", "name": "Quels traitements ciblent le PRC1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de la méthylation des histones et des thérapies géniques sont explorés." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace contre les anomalies du PRC1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie peut être utilisée, mais son efficacité dépend du type de cancer associé." } }, { "@type": "Question", "name": "Des traitements expérimentaux existent-ils pour le PRC1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation dans des essais cliniques." } }, { "@type": "Question", "name": "Le PRC1 peut-il être ciblé par des médicaments spécifiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours pour développer des médicaments ciblant spécifiquement le PRC1." } }, { "@type": "Question", "name": "Les thérapies combinées sont-elles efficaces pour le PRC1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies combinées peuvent améliorer l'efficacité des traitements contre les cancers liés au PRC1." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le PRC1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers avancés et des troubles de développement sévères." } }, { "@type": "Question", "name": "Le PRC1 est-il lié à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien potentiel entre le PRC1 et certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Le PRC1 affecte-t-il la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anomalies du PRC1 peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des complications neurologiques associées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies du PRC1 peuvent entraîner des complications neurologiques, comme des troubles cognitifs." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour le PRC1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour le PRC1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains types de cancers liés au PRC1 sont plus fréquents chez les personnes âgées." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le PRC1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des expositions à des agents cancérigènes peuvent augmenter le risque d'anomalies du PRC1." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque de PRC1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains cancers liés au PRC1 montrent des différences de prévalence entre les sexes." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque de PRC1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie malsain, comme le tabagisme, peut augmenter le risque d'anomalies du PRC1." } } ] } ] }

Sources (10000 au total)

Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.

Sacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive patients, but the best dose remains unclear. We performed this network meta-analysis to determine the comparative ef... We searched four databases for relevant studies published before January 2022. Mean systolic and diastolic blood pressures in the sitting position (msSBP and msDBP) and ambulatory condition (24-h maSB... In hypertensive patients, 200 mg once daily of sacubitril/valsartan may exert a greater reduction in ambulatory blood pressure than 100 mg once daily and 200 mg once daily may not be inferior to 400 m...

Herbal Medicines for Rhinosinusitis: A Systematic Review and Network Meta-analysis.

To analyze and compare the effects of herbal medicines (HMs) for treating different forms of rhinosinusitis.... Forty-seven randomized controlled trials evaluating 18 HMs in six different rhinosinusitis populations were included in the network meta-analysis. Certainty of evidence was assessed using the Grading ... PROSPERO ID: CRD42022328265 May 10, 2022....

Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.

There are limited pooled data showing the impact of visceral metastasis on oncologic outcomes in metastatic prostate cancer patients treated with combination systemic therapies. We aimed to analyze an... Three databases were queried in July 2022 for randomized, controlled trials analyzing metastatic prostate cancer patients treated with combination systemic therapy (androgen receptor signaling inhibit... Overall, 12 and 8 randomized, controlled trials were included for systematic review and meta-analyses/network meta-analyses, respectively. In metastatic hormone-sensitive prostate cancer patients, add... Despite aggressive clinical behavior and worse trajectory of metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer with visceral metastasis, the effectivenes...

crossnma: An R package to synthesize cross-design evidence and cross-format data using network meta-analysis and network meta-regression.

Although aggregate data (AD) from randomised clinical trials (RCTs) are used in the majority of network meta-analyses (NMAs), other study designs (e.g., cohort studies and other non-randomised studies... We developed the R package crossnma to perform cross-format (IPD and AD) and cross-design (RCT and NRS) NMA and network meta-regression (NMR). The models are implemented as Bayesian three-level hierar... The R package crossnma enables the user to perform NMA and NMR with different data types in a Bayesian framework and facilitates the inclusion of all types of evidence recognising differences in risk ...

The impact of timing on outcomes in appendicectomy: a systematic review and network meta-analysis.

Appendicectomy remains the standard treatment for appendicitis. There is a lack of clarity on the timeframe in which surgery should be performed to avoid unfavourable outcomes.... To perform a systematic review and network meta-analysis to evaluate the impact the (1)time-of-day surgery is performed (2), time elapsed from symptom onset to hospital presentation (patient time) (3)... A systematic review was performed as per PRISMA-NMA guidelines. The time-of-day which surgery was done was divided into day, evening and night. The other groups were divided into < 24 h, 24-48 h and >... Sixteen studies were included with a total of 232,678 patients. The time of day at which surgery was performed had no impact on outcomes. The incidence of complicated appendicitis, post-operative comp... Appendicectomy within 24 h of hospital admission is associated with improved outcomes compared to patients having surgery 24-48 and > 48 h after admission. The time-of-day which surgery is performed d...

Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review.

Preeclampsia (PE) is a pregnancy disorder that represents a major cause of maternal and perinatal morbidity and mortality.... This network meta-analysis was registered with PROSPERO. We searched the PubMed, ClinicalTrials.gov. and Embase databases for studies published from inception to the 31... We included eight randomized controlled trials (RCTs) involving a total of 1192 women with PE; two studies were of high quality and six were of moderate quality. Eight interventions were addressed in ... According to the eight RCTs included in this study, Diltiazem was the most effective in reducing blood pressure in PE patients; Labetalol and Nicardipine also had good effects. Diltiazem is preferred ...

Effective luting agents for glass-fiber posts: A network meta-analysis.

The aims of this study were to systematically review the literature and compare the relative effects of various luting agents on bonding between glass-fiber posts and root canal dentin in short- and l... The literature was electronically searched in PubMed, Embase, and Scopus. A manual search was performed by scanning the reference lists of the included studies.... Two reviewers independently conducted the selection of studies, data extraction, and risk of bias assessment. Pairwise meta-analyses were based on random effect models. Network meta-analyses were cond... One hundred and eighteen studies were included and assessed the effects of five luting agents. For pairwise meta-analyses, in short-term aging conditions, a significantly higher bond strength of self-... The SARC tended to be the most effective luting agent in bonding between glass-fiber posts and root canal dentin in short- and long-term aging conditions....